Capillary Leak Syndrome
Capillary Permeability
Leukemia, Hairy Cell
Sialic Acid Binding Ig-like Lectin 2
Drug Approval
Cladribine
United States Food and Drug Administration
Pentostatin
Device Approval
Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. (1/91)
The dose-limiting toxicity of interleukin-2 (IL-2) and immunotoxin (IT) therapy in humans is vascular leak syndrome (VLS). VLS has a complex etiology involving damage to vascular endothelial cells (ECs), extravasation of fluids and proteins, interstitial edema, and organ failure. IL-2 and ITs prepared with the catalytic A chain of the plant toxin, ricin (RTA), and other toxins, damage human ECs in vitro and in vivo. Damage to ECs may initiate VLS; if this damage could be avoided without losing the efficacy of ITs or IL-2, larger doses could be administered. In this paper, we provide evidence that a three amino acid sequence motif, (x)D(y), in toxins and IL-2 damages ECs. Thus, when peptides from RTA or IL-2 containing this sequence motif are coupled to mouse IgG, they bind to and damage ECs both in vitro and, in the case of RTA, in vivo. In contrast, the same peptides with a deleted or mutated sequence do not. Furthermore, the peptide from RTA attached to mouse IgG can block the binding of intact RTA to ECs in vitro and vice versa. In addition, RTA, a fragment of Pseudomonas exotoxin A (PE38-lys), and fibronectin also block the binding of the mouse IgG-RTA peptide to ECs, suggesting that an (x)D(y) motif is exposed on all three molecules. Our results suggest that deletions or mutations in this sequence or the use of nondamaging blocking peptides may increase the therapeutic index of both IL-2, as well as ITs prepared with a variety of plant or bacterial toxins. (+info)Intrapulmonary protein leakage in immunocompromised children and adults with pneumonia. (2/91)
BACKGROUND: Pulmonary infections are associated with an increase in capillary permeability but information regarding age related differences in the local inflammatory response is lacking. To quantify the degree of capillary leakage during inflammation, the concentrations of the plasma proteins albumin, alpha1-antitrypsin, alpha2-macroglobulin and the locally produced proteins elastase, myeloperoxidase, lactoferrin and fibronectin were studied in the bronchoalveolar lavage (BAL) fluid of immunosuppressed children and adults with pneumonia. METHODS: Sixteen children aged 2-16 years and 15 adults who developed pneumonia while receiving immunosuppressive therapy for haematological malignancies were included in the study. Bronchoalveolar lavage was performed via a flexible bronchoscope with three aliquots of 1 ml/kg body weight in children and 200 ml in adults. Protein concentrations in BAL fluid were determined using highly sensitive immunoluminometric assays. RESULTS: Despite considerable variability, the median concentrations of all proteins in BAL fluid were significantly higher in both patient populations than in previously collected age adjusted reference values. The concentrations of serum derived proteins were significantly higher in children with pneumonia than in adult patients. In contrast, no differences were observed between the two groups for locally produced proteins. CONCLUSIONS: These data suggest that the degree of protein exudation is more pronounced in immunosuppressed children with pneumonia than in adults in a similar clinical situation. This is in agreement with our studies in healthy individuals and may reflect a greater permeability of the alveolar-capillary membrane in children, regardless of disease status. (+info)Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2. (3/91)
At sites of chronic inflammation seen during infections, autoimmunity, graft-vs-host response, and cytokine therapy, endothelial cell injury is known to occur, the exact mechanism of which is unknown. In the current study we used IL-2-induced vascular leak syndrome (VLS) as a model to investigate whether cytotoxic lymphocytes use CD44 in mediating endothelial cell injury. Administration of IL-2 to wild-type mice triggered significant VLS in the lungs and liver. In contrast, in CD44 knockout (KO) mice, IL-2-induced VLS was markedly reduced in the lungs and liver. IL-2-treated wild-type and CD44 KO mice had similar levels of perivascular infiltration with lymphocytes in the lungs and liver. This suggested that the decrease in VLS seen in CD44 KO mice was not due to the inability of lymphocytes to migrate to these organs. Ultrastructural studies demonstrated extensive endothelial cell damage in the lungs and liver of IL-2-treated wild-type, but not CD44 KO, mice. Moreover, CD44-KO mice exhibited a marked decrease in IL-2-induced lymphokine-activated killer cell activity. The induction of VLS was dependent on the expression of CD44 on immune cells rather than endothelial cells because adoptive transfer of CD44+, but not CD44- spleen cells along with IL-2 into CD44 KO mice triggered VLS. The IL-2-induced VLS was blocked by administration of F(ab')2 of Abs against CD44. The current study demonstrates that CD44 plays a key role in endothelial cell injury. Blocking CD44 in vivo may offer a novel therapeutic approach to prevent endothelial cell injury by cytotoxic lymphocytes in a variety of clinical disease models. (+info)Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats in vivo. (4/91)
Advanced glycation end products (AGEs) are nonenzymatic glycosylated adducts of proteins that accumulate in vascular tissue during diabetes and aging. The aim of this work was to study the role of AGEs and of the oxidative mechanisms in diabetes-induced changes in vascular permeability. Intravital videomicroscopy was used to study albumin microvascular leakage in cremaster muscle. The extravasation of a fluorescent macromolecular tracer (fluorescein isothiocyanate-albumin) was measured for 1 h and, after computer-aided image analysis, was expressed as variations of normalized gray levels (arbitrary units). Extravasation of the macromolecular tracer was much higher in diabetic rats than in control rats (slope of extravasation versus time increased by >100%, P < 10(-4)). This increase was significantly inhibited when we blocked AGEs binding to their endothelial receptor by intravenous bolus of soluble recombinant receptor to AGEs (rR-RAGE) (slope of extravasation versus time decreased by 19, 30, and 40%, for 0.5, 2.5, and 5.15 mg/kg rR-RAGE, respectively) or by a 6 mg/kg intravenous bolus of antibody against RAGE (slope decreased by 53%). Systemic injection of probucol (an antioxidant) also significantly inhibited the increase in the extravasation of the macromolecular tracer occurring in experimental diabetes (slope decreased by 51%, P < 10(-4)). These results strongly suggest that in experimental diabetes the interaction of circulating AGEs and endothelial RAGE mediates albumin micro-vascular leakage, possibly via AGE-RAGE-dependent enhanced oxidant stress. (+info)Adjuvant treatment of severe acute pancreatitis with C1 esterase inhibitor concentrate after haematopoietic stem cell transplantation. (5/91)
BACKGROUND: With an incidence of 4%, acute pancreatitis is a common complication of bone marrow or peripheral haematopoietic stem cell transplantation, which contributes significantly to morbidity and mortality in these patients. In most cases, the pathogenesis of acute pancreatitis cannot be attributed to a single pathogenetic factor, as treatment toxicity, acute graft versus host disease, infection, and cholestasis may all contribute. Acute pancreatitis is characterised by inflammation and activation of digestive proenzymes leading to autodigestive destruction of the pancreas and systemic activation of protease cascades including the complement system. AIM: To describe the effects of human C1 esterase inhibitor in two children, who developed severe acute pancreatitis with considerable complement activation after allogeneic haematopoietic stem cell transplantation. METHODS: Both children showed clinical features resembling those observed in capillary leakage syndrome. In both patients, treatment with C1 esterase inhibitor concentrate contributed to a rapid clinical stabilisation. CONCLUSIONS: These observations strongly support the proposed pathophysiological concept that early treatment with C1 esterase inhibitor interferes with the activation of the complement system in acute pancreatitis. Inhibition of complement activation prevents its adverse effects on vascular function and permeability, and thus stabilises intravascular fluid status and prevents multiorgan failure in acute pancreatitis. (+info)Effect of endothelin and endothelin receptor blockade on capillary permeability in experimental pancreatitis. (6/91)
BACKGROUND: Capillary leakage with fluid loss into the third space contributes to many of the early systemic complications in severe acute pancreatitis. There has been increasing interest in endothelin as one of the factors affecting capillary permeability. AIM: To elucidate further the role of endothelin in the development of capillary leakage in acute pancreatitis by investigating the effect of exogenous endothelin administration and endothelin receptor blockade in sham operated animals and two models of acute pancreatitis. METHODS: Determination of capillary permeability in the pancreas and colonic mucosa by quantifying extravasation of fluorescein labelled dextran using a novel computer assisted video image analysis system. RESULTS: Pancreatic and colonic capillary permeability increased stepwise from mild to severe acute pancreatitis. Endothelin increased pancreatic and colonic capillary permeability in healthy animals and animals with mild acute pancreatitis but had no additional adverse effect in severe acute pancreatitis. Endothelin receptor blockade decreased pancreatic capillary permeability in sham operated rats but had no effect on the colon. In mild and severe acute pancreatitis, endothelin receptor blockade stabilised increased capillary permeability in both the pancreas and colon. CONCLUSIONS: Endothelin plays an important role in mediating capillary permeability in the pancreas. In severe pancreatitis, it increases capillary permeability even outside the pancreas, thereby contributing to capillary leakage. Endothelin receptor blockade significantly reduces capillary permeability in acute pancreatitis both in and outside the pancreas, suggesting a therapeutic approach to counteract capillary leakage in severe acute pancreatitis. (+info)Sensitive blood-retinal barrier breakdown quantitation using Evans blue. (7/91)
PURPOSE: This study investigated whether a nonradioactive dye, Evans blue, can be adapted as a safe alternative to the isotope-dilution method for quantitating blood-retinal barrier breakdown. METHODS: Blood-retinal barrier breakdown was induced in rats with vascular endothelial growth factor (VEGF) or through the induction of diabetes. After allowing Evans blue to circulate in the vasculature, the dye was cleared from the bloodstream with saline, citrate, or citrate-buffered paraformaldehyde, and the efficacies of the perfusion solutions were compared. Extravasated dye was detected at 620 nm and was normalized against the time-averaged Evans blue plasma concentration, the circulation time, and also against wet and dry retina weights. RESULTS: Evans blue leakage from retinas treated with VEGF was 4.0-fold higher than that of contralateral untreated eyes (n = 6 rats, P: < 0.05). Retinal Evans blue leakage of eyes from 1-week diabetic animals (n = 11 retinas) was 1.7-fold higher (P: < 0.05) than that of nondiabetic controls (n = 10 retinas). Intra-animal, inter-retina weights showed significantly less variability (P: < 0.05) with the use of dry weights (11.2%, n = 74 retina pairs) than with wet weights (20.5%, n = 93 retina pairs). CONCLUSIONS: The Evans blue dye technique can be modified to be as sensitive and quantitative as the isotope-dilution method for measuring blood-retinal barrier breakdown. The advantages of the Evans blue technique are its safety, relative simplicity, and economy. (+info)The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. (8/91)
A retrospective analysis of 102 patients with relapsed, non-Hodgkin's lymphoma treated with two different ricin A chain-containing immunotoxins (ITs) in five Phase I clinical trials indicates that the dose-limiting toxicity, vascular leak syndrome, was more frequent and more severe in patients who had undergone prior radiotherapy (RT). Excluding patients with prior RT from the calculations of the maximum tolerated dose indicates that the maximum tolerated doses of these ITs had not been reached in any trial and are clearly higher than reported previously. Excluding patients with prior RT from future clinical trials may increase the dose of ITs that can be given in the absence of severe vascular leak syndrome. (+info)Capillary leak syndrome (CLS) is a rare, but serious condition characterized by the abnormal leakage of plasma from the bloodstream into surrounding tissues. This occurs due to increased permeability of the capillary walls, which are the smallest blood vessels in the body that connect arterioles and venules, allowing for the exchange of nutrients, waste products, and gases between the blood and the tissues.
In CLS, the leakage of plasma leads to a rapid loss of intravascular volume, resulting in hypotension (low blood pressure), hemoconcentration (increased concentration of red blood cells due to reduced plasma volume), and edema (swelling) in various parts of the body. The fluid shift from the bloodstream to the tissues can also cause organ dysfunction and failure if not promptly treated.
The exact causes of capillary leak syndrome are not fully understood, but it can be associated with certain medical conditions, such as infections, autoimmune disorders, medications, or cancer. In some cases, CLS may occur without an identifiable underlying cause, known as idiopathic capillary leak syndrome.
Treatment for capillary leak syndrome typically involves supportive care to maintain blood pressure, replace lost fluids and electrolytes, and manage any organ dysfunction. Medications such as corticosteroids, immunoglobulins, or vasopressors may be used depending on the severity of the condition and the presence of underlying causes. In severe cases, extracorporeal membrane oxygenation (ECMO) or other intensive care interventions might be necessary to support organ function and ensure adequate blood flow.
Capillary permeability refers to the ability of substances to pass through the walls of capillaries, which are the smallest blood vessels in the body. These tiny vessels connect the arterioles and venules, allowing for the exchange of nutrients, waste products, and gases between the blood and the surrounding tissues.
The capillary wall is composed of a single layer of endothelial cells that are held together by tight junctions. The permeability of these walls varies depending on the size and charge of the molecules attempting to pass through. Small, uncharged molecules such as water, oxygen, and carbon dioxide can easily diffuse through the capillary wall, while larger or charged molecules such as proteins and large ions have more difficulty passing through.
Increased capillary permeability can occur in response to inflammation, infection, or injury, allowing larger molecules and immune cells to enter the surrounding tissues. This can lead to swelling (edema) and tissue damage if not controlled. Decreased capillary permeability, on the other hand, can lead to impaired nutrient exchange and tissue hypoxia.
Overall, the permeability of capillaries is a critical factor in maintaining the health and function of tissues throughout the body.
Hairy cell leukemia (HCL) is a rare, slow-growing type of cancer in which the bone marrow makes too many B cells (a type of white blood cell). These excess B cells are often referred to as "hairy cells" because they look abnormal under the microscope, with fine projections or "hair-like" cytoplasmic protrusions.
In HCL, these abnormal B cells can build up in the bone marrow and spleen, causing both of them to enlarge. The accumulation of hairy cells in the bone marrow can crowd out healthy blood cells, leading to a shortage of red blood cells (anemia), platelets (thrombocytopenia), and normal white blood cells (leukopenia). This can result in fatigue, increased risk of infection, and easy bruising or bleeding.
HCL is typically an indolent disease, meaning that it progresses slowly over time. However, some cases may require treatment to manage symptoms and prevent complications. Treatment options for HCL include chemotherapy, immunotherapy, targeted therapy, and stem cell transplantation. Regular follow-up with a healthcare provider is essential to monitor the disease's progression and adjust treatment plans as needed.
Siglec-2, also known as CD22, is a type of cell surface protein that belongs to the sialic acid-binding immunoglobulin-like lectins (Siglecs) family. It is primarily expressed on mature B cells and plays a crucial role in regulating B cell activation and function. Siglec-2 recognizes and binds to sialic acid residues on glycoproteins and gangliosides, which are sugars that are attached to proteins and lipids on the surface of cells. This binding can lead to inhibitory signals that dampen B cell activation and help prevent autoimmunity. Siglec-2 has also been implicated in the regulation of B cell migration and adhesion.
"Drug approval" is the process by which a regulatory agency, such as the US Food and Drug Administration (FDA), grants formal authorization for a pharmaceutical company to market and sell a drug for a specific medical condition. The approval process is based on rigorous evaluation of clinical trial data to ensure that the drug is safe and effective for its intended use.
The FDA's approval process typically involves several stages, including preclinical testing in the lab and animal studies, followed by three phases of clinical trials in human subjects. The first phase tests the safety of the drug in a small group of healthy volunteers, while the second and third phases test the drug's efficacy and side effects in larger groups of patients with the medical condition for which the drug is intended.
If the results of these studies demonstrate that the drug is safe and effective, the pharmaceutical company can submit a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA for review. The application includes data from the clinical trials, as well as information about the manufacturing process, labeling, and proposed use of the drug.
The FDA reviews the application and may seek input from independent experts before making a decision on whether to approve the drug. If approved, the drug can be marketed and sold to patients with the medical condition for which it was approved. The FDA continues to monitor the safety and efficacy of approved drugs after they reach the market to ensure that they remain safe and effective for their intended use.
Cladribine is a medication used in the treatment of certain types of cancer and multiple sclerosis. It is a type of drug called a purine nucleoside analog, which means it interferes with the production of DNA and RNA, the genetic material of cells. This can help to stop the growth and multiplication of abnormal cells in the body.
In cancer treatment, cladribine is used to treat hairy cell leukemia and certain types of lymphoma. In multiple sclerosis, it is used to reduce the frequency of relapses and slow down the progression of disability. Cladribine works by selectively targeting and depleting certain white blood cells called lymphocytes, which are thought to play a role in the immune response that damages the nervous system in multiple sclerosis.
Cladribine is usually given as an injection into a vein or under the skin, and it may be given on its own or in combination with other medications. Common side effects of cladribine include nausea, vomiting, diarrhea, and weakness. It can also lower the body's ability to fight infections, so patients may need to take precautions to avoid infection while receiving treatment. Cladribine should be used with caution in people with a history of certain medical conditions, such as liver or kidney disease, and it should not be used during pregnancy or breastfeeding.
The United States Food and Drug Administration (FDA) is a federal government agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our country's food supply, cosmetics, and products that emit radiation. The FDA also provides guidance on the proper use of these products, and enforces laws and regulations related to them. It is part of the Department of Health and Human Services (HHS).
Pentostatin is a medication used in the treatment of certain types of cancer, including hairy cell leukemia and certain T-cell lymphomas. It is a type of drug called a purine nucleoside analog, which works by interfering with the production of DNA and RNA, the genetic material found in cells. This can help to stop the growth and multiplication of cancer cells.
Pentostatin is given intravenously (through an IV) in a healthcare setting, such as a hospital or clinic. It is usually administered on a schedule of every other week. Common side effects of pentostatin include nausea, vomiting, diarrhea, and loss of appetite. It can also cause more serious side effects, such as low blood cell counts, infections, and liver problems.
It's important to note that this is a medical definition of the drug and its use, and it should not be used as a substitute for professional medical advice. If you have any questions about pentostatin or your treatment, it is best to speak with your healthcare provider.
"Device approval" is a term used to describe the process by which a medical device is determined to be safe and effective for use in patients by regulatory authorities, such as the U.S. Food and Drug Administration (FDA). The approval process typically involves a rigorous evaluation of the device's design, performance, and safety data, as well as a review of the manufacturer's quality systems and labeling.
The FDA's Center for Devices and Radiological Health (CDRH) is responsible for regulating medical devices in the United States. The CDRH uses a risk-based classification system to determine the level of regulatory control needed for each device. Class I devices are considered low risk, Class II devices are moderate risk, and Class III devices are high risk.
For Class III devices, which include life-sustaining or life-supporting devices, as well as those that present a potential unreasonable risk of illness or injury, the approval process typically involves a premarket approval (PMA) application. This requires the submission of comprehensive scientific evidence to demonstrate the safety and effectiveness of the device.
For Class II devices, which include moderate-risk devices such as infusion pumps and powered wheelchairs, the approval process may involve a premarket notification (510(k)) submission. This requires the manufacturer to demonstrate that their device is substantially equivalent to a predicate device that is already legally marketed in the United States.
Once a medical device has been approved for marketing, the FDA continues to monitor its safety and effectiveness through post-market surveillance programs. Manufacturers are required to report any adverse events or product problems to the FDA, and the agency may take regulatory action if necessary to protect public health.
Capillary leak syndrome
Treatment of lung cancer
Interleukin 2
Gemcitabine
Oxford-AstraZeneca COVID-19 vaccine
Mehmet Ali Erbil
Targeted molecular therapy for neuroblastoma
COVID-19 vaccination in Bulgaria
Disseminated intravascular coagulation
Retinoic acid syndrome
Moxetumomab pasudotox
Acute promyelocytic leukemia
POEMS syndrome
Hematocrit
Sargramostim
Viral hemorrhagic fever
Urticarial syndromes
Arturo Porzecanski
Gleich's syndrome
List of diseases (C)
SCLS
Dinutuximab
Anasarca
Tagraxofusp
Paeniclostridium sordellii
Lipopolysaccharide
Polycythemia
List of syndromes
Irvine-Gass syndrome
Shortages related to the COVID-19 pandemic
Capillary leak syndrome - Wikipedia
Systemic capillary leak syndrome: report on 13 patients with special focus on course and treatment
Table 3 - Fatal Exacerbations of Systemic Capillary Leak Syndrome Complicating Coronavirus Disease - Volume 27, Number 10...
Drug-Induced Pulmonary Toxicity: Practice Essentials, Background, Pathophysiology
Capillary leak syndrome future or investigational therapies - wikidoc
SORIATANE (acitretin) Capsules
The Clinical Picture of Severe Systemic Capillary-Leak Syndrome Episodes Requiring ICU Admission
Systemic capillary leak syndrome presenting with fulminant recurrent cardiogenic shock<...
Udenyca: Package Insert - Drugs.com
DailyMed - FYLNETRA- pegfilgrastim injection
COVID-19 vaccines: Canadian Immunization Guide - Canada.ca
Nivestym (filgrastim-aafi) FDA Approval History - Drugs.com
Polycythemia as an Uncommon Finding in 2 Children, One With Systemic Capillary Leak Syndrome and the Other With Protein-losing...
Capillary leak syndrome and disseminated intravascular coagulation after kidney transplantation in a patient with hereditary...
FDA D.I.S.C.O.: FDA approval of moxetumomab pasudotox-tdfk for relapsed or refractory hairy cell leukemia | FDA
Reply to: Scoring the capillary leak syndrome: towards an individualized gradation of the vascular barrier injury | Annals of...
Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® ...
Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® ...
New Directions in Cancer Immunotherapy
Aldesleukin: MedlinePlus Drug Information
Relapsing Polychondritis: Symptoms, Diagnosis, and Treatment
Vaxzevria, suspension for injection, COVID 19 Vaccine (ChAdOx1 S [recombinant]) - Summary of Product Characteristics (SmPC) - ...
Immune cartography of macrophage activation syndrome in the COVID-19 era | Nature Reviews Rheumatology
Pneumotox » Drug » Methacrylate - Methylmethacrylate
Robert Promisloff, DO: Medicine: Pulmonary & Critical Care - Drexel University College of Medicine
Clinical Challenges: Blastic Plasmacytoid Dendritic Cell Neoplasm | MedPage Today
Pericardial Effusion: Practice Essentials, Background, Pathophysiology
Interleukin 2, Proleukin (aldesleukin) dosing, indications, interactions, adverse effects, and more
urofacial syndrome - Ontology Browser - Rat Genome Database
Prognostic Value of Serum Cholinesterase Activity in Severe SARS-CoV-2-Infected Patients Requiring Intensive Care Unit...
Systemic7
- Systemic capillary leak syndrome (SCLS), also called Clarkson's disease, or primary capillary leak syndrome, is a rare, grave and episodic medical condition observed largely in otherwise healthy individuals mostly in middle age. (wikipedia.org)
- Systemic capillary leak syndrome (SCLS) is a rare condition characterized by unexplained episodic capillary hyperpermeability due to a shift of fluid and protein from the intravascular to the interstitial space. (nih.gov)
- Polycythemia as an Uncommon Finding in 2 Children, One With Systemic Capillary Leak Syndrome and the Other With Protein-losing Enteropathy Caused by CD55 Deficiency. (bvsalud.org)
- We report 2 children with distinct causes of polycythemia , 1 from systemic capillary leak syndrome (SCLS) and the other from protein-losing enteropathy (PLE) caused by CD55 deficiency . (bvsalud.org)
- A hyperinflammatory 'cytokine storm' state termed macrophage activation syndrome (MAS), culminating from a complex interplay of genetics, immunodeficiency, infectious triggers and dominant innate immune effector responses, can develop across disparate entities including systemic juvenile idiopathic arthritis (sJIA) and its counterpart adult-onset Still disease (AOSD), connective tissue diseases, sepsis, infection, cancers and cancer immunotherapy. (nature.com)
- Consider the use of prophylactic steroids to mitigate Systemic Inflammatory Response Syndrome (SIRS) or capillary leak syndrome (e.g., hypotension, tachycardia, tachypnea, and pulmonary edema). (guidelinecentral.com)
- If you believe the bulletins put out by the American College of Rheumatology, we have pretty much conquered all of the well-known rheumatic conditions and are now simply investigating the really uncommon ones, such as Erdheim-Chester disease or systemic capillary leak syndrome ( The Rheumatologist , February 2017 and December 2016 ). (medscape.com)
Disseminated intravascul2
- HAE has a risk of life-threatening complications such as capillary leak syndrome (CLS) and disseminated intravascular coagulation (DIC). (anesth-pain-med.org)
- Besides the well-known clinical presentations, HAE may also produce hypovolemic shock due to the tissue leakage of fluids [ 4 ] and may lead to potentially life-threatening conditions such as capillary leak syndrome (CLS) and disseminated intravascular coagulation (DIC) [ 5 , 6 ]. (anesth-pain-med.org)
Monoclonal3
- Pharmaceuticals, including the chemotherapy medications gemcitabine and denileukin diftitox, as well as certain interleukins and monoclonal antibodies, can also cause capillary leaks. (wikipedia.org)
- The relationship between Capillary leak syndrome and post-episodic levels of monoclonal IgG are of interest and continue to be studied. (wikidoc.org)
- Studies continue to be done to understand the relationship between monoclonal IgG gammopathy and Capillary leak syndrome . (wikidoc.org)
Hypotension4
- The abdomen, the central nervous system, and the organs (including the lungs) are typically spared, but the extravasation in the extremities is sufficiently massive to cause circulatory shock and compartment syndromes, with a dangerous hypotension (low blood pressure), hemoconcentration (thickening of the blood) and hypoalbuminemia (drop in albumin, a major protein) in the absence of other causes for such abnormalities. (wikipedia.org)
- Discontinue Clolar administration if a patient shows early signs or symptoms of SIRS or capillary leak syndrome (e.g., hypotension, tachycardia, tachypnea, and pulmonary edema) occur and provide appropriate supportive measures. (guidelinecentral.com)
- In addition to hypotension, cytokines are likely to be important in the pathophysiology of acute kidney injury in capillary leak syndrome. (nephronpower.com)
- hypovolemia and hypotension can cause organ injury, whereas capillary leakage of administered fluid can worsen organ edema leading to progressive organ injury. (nephronpower.com)
ARDS3
- Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress. (drugs.com)
- Acute Respiratory Distress Syndrome (ARDS). (drugs.com)
- A serious lung problem called Acute Respiratory Distress Syndrome (ARDS). (neulasta.com)
Pulmonary edema1
- Meanwhile, there was a severe pulmonary edema and capillary leak syndrome. (sermo.com)
Hemophagocytic lymphohistiocytosis1
- It is a phenomenon most commonly witnessed in sepsis, and less frequently in autoimmune diseases, differentiation syndrome, engraftment syndrome, hemophagocytic lymphohistiocytosis, the ovarian hyperstimulation syndrome, viral hemorrhagic fevers, and snakebite and ricin poisoning. (wikipedia.org)
Fluid3
- Nivestym can cause fluid to leak from blood vessels into your body's tissues. (drugs.com)
- Aldesleukin may cause a severe and life-threatening reaction called capillary leak syndrome (a condition that causes the body to keep excess fluid, low blood pressure, and low levels of a protein [albumin] in the blood) which may result in damage to your heart, lungs, kidneys, and gastrointestinal tract. (medlineplus.gov)
- A condition characterized by recurring episodes of fluid leaking from capillaries into extra-vascular compartments causing hematocrit to rise precipitously. (bvsalud.org)
Macrophage activati1
- Although macrophage activation syndrome (MAS) is often termed autoinflammatory in both loss and gain of function phenotypes, adaptive lineage cells, especially T cells, are clearly important in both settings. (nature.com)
Vascular1
- Capillary leak syndrome, or vascular leak syndrome, is characterized by the escape of blood plasma through capillary walls, from the blood circulatory system to surrounding tissues, muscle compartments, organs or body cavities. (wikipedia.org)
Neulasta1
- If you have breast cancer or lung cancer, when Neulasta ® is used with chemotherapy and radiation therapy, or with radiation therapy alone, you may have an increased risk of developing a precancerous blood condition called myelodysplastic syndrome (MDS) or a blood cancer called acute myeloid leukemia (AML). (neulasta.com)
Disease2
- Novel coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). (canada.ca)
- Nephrotic syndrome is neither a single gested that IL-1 has a significant role in the disease nor even a heterogeneous group of immunopathogenesis of proteinuria [ 7 ] and related diseases. (who.int)
Thrombocytopenia2
- Individuals who have experienced thrombosis with thrombocytopenia syndrome (TTS) following vaccination with Vaxzevria (see section 4.2). (medicines.org.uk)
- Serious adverse events included capillary leak syndrome, hepatic dysfunction, and thrombocytopenia. (medpagetoday.com)
Cytokine5
- Many scenarios, including infection, aberrant immunity, cancer and cancer immunotherapy, are associated with cytokine storm, also known as cytokine release syndrome (CRS) or hypercytokinaemia. (nature.com)
- Among the 170 Yescarta-treated patients evaluable for safety, Grade ≥3 cytokine release syndrome (CRS) and neurologic events were observed in 6% and 21% of patients, respectively. (gilead.com)
- In the safety analysis set (n=146), Grade 3 or higher cytokine release syndrome (CRS) and neurologic toxicities occurred in 8 percent and 21 percent of patients, respectively. (gilead.com)
- Blincyto carries a boxed warning that some clinical trial participants had problems with cytokine release syndrome (CRS), or neurological toxicities which may be life threatening or fatal (FDA, 2014). (southcarolinablues.com)
- Life-threatening or fatal cytokine release syndrome (CRS) occurred in patients receiving blinatumomab (Amgen, 2014). (southcarolinablues.com)
Episodes2
- It is characterized by self-reversing episodes during which the endothelial cells which line the capillaries, usually of the extremities, separate for one to three days, causing a leakage of plasma mainly into the muscle compartments of the arms and legs. (wikipedia.org)
- Individuals who have previously experienced episodes of capillary leak syndrome (see also section 4.4). (medicines.org.uk)
Myelodysplastic Syndrome2
- Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): Monitor patients with breast and lung cancer using UDENYCA in conjunction with chemotherapy and/or radiotherapy for signs and symptoms of MDS/AML. (drugs.com)
- Myelodysplastic syndrome and acute myeloid leukemia. (neulasta.com)
Severe1
- The streptococcal toxic shock syndrome is a severe illness associated with invasive or noninvasive group A streptococcal ( Streptococcus pyogenes ) infection. (cdc.gov)
Kidney1
- It is produced by Idiopathic nephrotic syndrome (INS) a variety of cells, including monocytes and accounts for 90% of nephrosis in child- mesangial cells in the kidney [ 9 ]. (who.int)
Dysfunction2
- Heart Failure (HF) Heart failure (HF) is a syndrome of ventricular dysfunction. (msdmanuals.com)
- minimal change nephrotic syndrome possible at present to distinguish whether is found in approximately 85% of INS, IL-6 contributes to renal dysfunction or mesangial proliferative glomerulonephritis whether it reflects renal damage [ 10 ]. (who.int)
Edema1
- or evidence of diffuse capillary leak manifested by acute onset of generalized edema, or pleural or peritoneal effusions with hypoalbuminemia. (cdc.gov)
Occur2
- Capillary leak syndrome may occur immediately after aldesleukin is given. (medlineplus.gov)
- Capillary leak syndrome also may occur. (medscape.com)
20161
- From 1999 through April 2016, Dr. Mertz was the principal investigator at the National Institutes of Health International Collaborations in infectious diseases research grant U19/U01 focused on epidemiology, natural history and management of hantavirus cardiopulmonary syndrome in Chile and Panama. (cdc.gov)
Shock1
- however, laboratory evidence may be one component of a clinical definition (e.g., toxic-shock syndrome). (cdc.gov)
Patients3
- Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). (drugs.com)
- for their insightful and pertinent comments regarding our study, which aimed at better defining the clinical characteristics of critically ill patients showing capillary leak syndrome (CLS) [ 1 ]. (springeropen.com)
- He has cared for patients with hantavirus cardiopulmonary syndrome since 1993. (cdc.gov)
Abstract1
- ABSTRACT We studied 60 children affected with idiopathic nephrotic syndrome (INS) plus 20 age and sex matched controls. (who.int)
Condition1
- This condition is called "Capillary Leak Syndrome" (CLS). (drugs.com)
Blood2
- CLS is associated with swelling that is caused by fluids leaking out of blood vessels into surrounding tissues. (proleukin.com)
- Janssen also comes with a few warnings for rare reactions, including blood clots with low levels of blood platelets, capillary leak syndrome and Guillain-Barré syndrome (GBS). (yukon-news.com)
Treatment1
- He was the site principal investigator for a CDC sponsored open trial of IV Ribavirin and subsequently the overall principle investigator through a National Institutes of Health collaborative antiviral study group sponsored controlled trial of IV Ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. (cdc.gov)
Conditions1
- These conditions and factors are sources of secondary capillary leak syndrome. (wikipedia.org)
Administration1
- Proleukin administration has been associated with capillary leak syndrome (CLS). (proleukin.com)
Overview1
- Overview of the Syndrome. (msdmanuals.com)
Children2
- 10%. In the remaining 10% of children with lecular weight protein found on the surface nephrotic syndrome, it is largely mediated of all nucleated cells which synthesize it. (who.int)
- minimal change nephrotic reabsorption and increased urinary excre- syndrome is most common in children 2-4 tion of -2-m [ 11 ]. (who.int)